{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:21:51Z","timestamp":1777922511933,"version":"3.51.4"},"reference-count":240,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:p>One of the most potent therapeutic and diagnostic agents in contemporary medicine is the monoclonal antibody (mAb). mAbs can perform a variety of tasks in breast cancer (BC), including identifying and delivering therapeutic medications to targets, preventing cell development, and suppressing immune system inhibitors including directly attacking cancer cells. mAbs are one of the most effective therapeutic options, particularly for HER2, but they have not been well studied for their use in treating other forms of BC, particularly triple negative breast tumors. Bispecific and trispecific mAbs have created new opportunities for more targeted specific efficacy, which has a positive impact on the viability of antigen specificity. They are more versatile and effective than other forms of treatment, emerging as most popular option for treating BC. However, mAbs have a limit in treatment due to certain adverse effects, including fever, shaking, exhaustion, headache, nausea, and vomiting, as well as rashes, bleeding, and difficulty breathing. To examine the current and prospective future capacities of mAbs with regard to the detection and treatment of BC, the present review highlights advantages and disadvantages of mAb approach.<\/jats:p>","DOI":"10.1089\/mab.2024.0018","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T06:33:37Z","timestamp":1743575617000},"page":"17-39","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment"],"prefix":"10.1177","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-6257","authenticated-orcid":false,"given":"Rahaman","family":"Shaik","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Education &amp; Research, Jamia Hamdard, New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varikuppala","family":"Mounika","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad-501510, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shireen","family":"Begum","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad-501510, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agolapu","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad-501510, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bathurasi","family":"Mallikarjun","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad-501510, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vollala","family":"Sri Harshini","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad-501510, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajini","family":"Kolure","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad-501510, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basavaraju","family":"Sreevani","sequence":"additional","affiliation":[{"name":"School of Health Sciences, University of New Haven, Connecticut, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Thakur","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, St. Pauls College of Pharmacy, Turkayamjal, Hyderabad-501510, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"e_1_3_6_2_2","volume-title":"To kill two birds with one stone: Targeting myeloid cells in cancers","author":"Mao Y","year":"2015","unstructured":"Mao Y. To kill two birds with one stone: Targeting myeloid cells in cancers. Karolinska Institutet. (Sweden); 2015."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.05.003"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182395"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042288"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781003463191-12"},{"issue":"42","key":"e_1_3_6_8_2","first-page":"4729","article-title":"Promising targets in anti-cancer drug development: Recent updates","volume":"24","author":"Kumar B","year":"2017","unstructured":"Kumar B, , Singh S, , Skvortsova I, et al. Promising targets in anti-cancer drug development: Recent updates. Curr Med Chem, 2017; 24(42):4729\u20134752.","journal-title":"Curr Med Chem"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-35955-9.00022-2"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2013.11.002"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.44313"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-30472-4_3"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.535"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21184"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11780"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-015-9625-z"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-007-7388-0"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102569"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15209"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2022.106988"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2018.05.001"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6109(05)70434-5"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071712"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.6.734"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153695"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-2080-4"},{"key":"e_1_3_6_27_2","volume-title":"Diagnostic pathology: breast","author":"Lester SC","year":"2016","unstructured":"Lester SC, , Hicks DG. Diagnostic pathology: breast. Elsevier Health Sciences; 2016."},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01235-16"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-804003-4.00013-X"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.2.112"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203543"},{"issue":"3","key":"e_1_3_6_32_2","first-page":"157","article-title":"Metastasis: A review of recent advances","volume":"17","author":"Zeidman I","year":"1957","unstructured":"Zeidman I. Metastasis: A review of recent advances. Cancer Res, 1957; 17(3):157\u2013162.","journal-title":"Cancer Res"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.1-1-8"},{"key":"e_1_3_6_34_2","volume-title":"Introduction to cancer metastasis","author":"Ahmad A","year":"2016","unstructured":"Ahmad A, editor. Introduction to cancer metastasis. Academic Press; 2016."},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)01034-5"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184620"},{"issue":"12","key":"e_1_3_6_37_2","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina MA","year":"2001","unstructured":"Molina MA, , Codony-Servat J, , Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 2001; 61(12):4744\u20134749.","journal-title":"Cancer Res"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21434"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27172"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2017.07.002"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413513"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06710-4"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1296341"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0113"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1628"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1635115"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01391-1"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.014"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867330666230505165031"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.24.2081"},{"issue":"3","key":"e_1_3_6_51_2","first-page":"559","article-title":"Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs","volume":"11","author":"Boulikas T","year":"2004","unstructured":"Boulikas T, , Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep, 2004; 11(3):559\u2013595.","journal-title":"Oncol Rep"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235999"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31704-7"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040435"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314672"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00796-4"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.9b01106"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030352"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.5579"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111756"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.262691"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163860"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219060-00004"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801533"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.003"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1976.220"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5913"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00607-16"},{"key":"e_1_3_6_69_2","unstructured":"Akce M Hu-Lieskovan S Reilley M et al. A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3)."},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2011.06.004"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-024-00687-6"},{"key":"e_1_3_6_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.10.008"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.08.027"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1137"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/11795549221099869"},{"key":"e_1_3_6_76_2","doi-asserted-by":"publisher","DOI":"10.56557\/ajoair\/2024\/v7i14046"},{"issue":"7","key":"e_1_3_6_77_2","first-page":"3121","article-title":"Cancer causes and treatments","volume":"11","author":"Saini A","year":"2020","unstructured":"Saini A, , Kumar M, , Bhatt S, et al. Cancer causes and treatments. Int. J. Pharm. Sci. Res, 2020; 11(7):3121\u20133134.","journal-title":"Int. J. Pharm. Sci. Res"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1304"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00500-3"},{"key":"e_1_3_6_80_2","first-page":"199","volume-title":"Nanotechnology Based Strategies for Cancer Immunotherapy: Concepts, Design, and Clinical Applications","author":"Mehta A","year":"2025","unstructured":"Mehta A, , Kulkarni N, , Khot SS. Monoclonal Antibodies-Based Approaches in Cancer Immunotherapy. In Nanotechnology Based Strategies for Cancer Immunotherapy: Concepts, Design, and Clinical Applications, 2025 (pp. 199\u2013247). Singapore: Springer Nature Singapore."},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-90951-8.00010-2"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071249"},{"key":"e_1_3_6_83_2","unstructured":"Karvonen H. The Role of ROR1 Pseudokinase Signaling in Cancer."},{"key":"e_1_3_6_84_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1025753"},{"key":"e_1_3_6_85_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000495"},{"key":"e_1_3_6_86_2","article-title":"Proteomic assessment of SKBR3\/HER2+ breast cancer cellular response to Lapatinib and Investigational Ipatasertib Kinase Inhibitors","author":"Karcini A","year":"2024","unstructured":"Karcini A, , Mercier NR, , Lazar IM. Proteomic assessment of SKBR3\/HER2+ breast cancer cellular response to Lapatinib and Investigational Ipatasertib Kinase Inhibitors. bioRxiv, 2024.","journal-title":"bioRxiv"},{"key":"e_1_3_6_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad026"},{"key":"e_1_3_6_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-018-4427-x"},{"key":"e_1_3_6_89_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01341-0"},{"key":"e_1_3_6_90_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082278"},{"key":"e_1_3_6_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.037"},{"key":"e_1_3_6_92_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-3-199508010-00009"},{"key":"e_1_3_6_93_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2084"},{"key":"e_1_3_6_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.03.006"},{"key":"e_1_3_6_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231175440"},{"key":"e_1_3_6_96_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061573"},{"key":"e_1_3_6_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.011"},{"key":"e_1_3_6_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00849-9"},{"key":"e_1_3_6_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.12.011"},{"key":"e_1_3_6_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.04.009"},{"key":"e_1_3_6_101_2","unstructured":"Abdalameer WA. Study of side effects associated with Biotherapy (Herceptin) in Breast Cancer-Patients in Al Hilla city Iraq (Doctoral dissertation College of Pharmacy university of Babylon)."},{"issue":"10","key":"e_1_3_6_102_2","first-page":"2103","article-title":"Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer","volume":"9","author":"Xuhong JC","year":"2019","unstructured":"Xuhong JC, , Qi XW, , Zhang Y, et al. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res, 2019; 9(10):2103\u20132119.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_6_103_2","unstructured":"Adhikari S Yousef JM Sumardy F et al. The application of DIA-MS coupled with PISA TPP for drug-target deconvolution."},{"key":"e_1_3_6_104_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181bd0445"},{"key":"e_1_3_6_105_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08601-1"},{"key":"e_1_3_6_106_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00303"},{"key":"e_1_3_6_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102500"},{"key":"e_1_3_6_108_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S281599"},{"key":"e_1_3_6_109_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1165781"},{"key":"e_1_3_6_110_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn539"},{"key":"e_1_3_6_111_2","volume-title":"Diseases of the nervous system","author":"Sontheimer H","year":"2021","unstructured":"Sontheimer H. Diseases of the nervous system. Elsevier; 2021."},{"key":"e_1_3_6_112_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3828-6"},{"key":"e_1_3_6_113_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0737-3"},{"key":"e_1_3_6_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604941"},{"key":"e_1_3_6_115_2","unstructured":"Sikokis A. Evaluation of adaptive and innate immune mechanisms of action of Pertuzumab plus Trastuzumab against HER2-positive breast cancer."},{"key":"e_1_3_6_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2013.07.029"},{"key":"e_1_3_6_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.714"},{"key":"e_1_3_6_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800267-4.00003-1"},{"key":"e_1_3_6_119_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S126424"},{"key":"e_1_3_6_120_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.8b00396"},{"key":"e_1_3_6_121_2","volume-title":"Synthesis and characterization of collagenous peptide-amphiphiles","author":"Yu YC","year":"1997","unstructured":"Yu YC. Synthesis and characterization of collagenous peptide-amphiphiles. University of Minnesota; 1997."},{"key":"e_1_3_6_122_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00169"},{"key":"e_1_3_6_123_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-7876-8_9"},{"key":"e_1_3_6_124_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0470"},{"key":"e_1_3_6_125_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061441"},{"key":"e_1_3_6_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202100272"},{"key":"e_1_3_6_127_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170817152554"},{"key":"e_1_3_6_128_2","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12125"},{"key":"e_1_3_6_129_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01376"},{"key":"e_1_3_6_130_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-005-6192-2"},{"key":"e_1_3_6_131_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652410793384150"},{"key":"e_1_3_6_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0272-z"},{"key":"e_1_3_6_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-394802-1.00001-7"},{"key":"e_1_3_6_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003"},{"key":"e_1_3_6_135_2","first-page":"33","article-title":"Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy","volume":"13","author":"Cruz E","year":"2019","unstructured":"Cruz E, , Kayser V. Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy. Biologics, 2019; 13:33\u201351.","journal-title":"Biologics"},{"key":"e_1_3_6_136_2","doi-asserted-by":"publisher","DOI":"10.1159\/000066203"},{"issue":"2","key":"e_1_3_6_137_2","first-page":"017","article-title":"Hybridoma technology for production of monoclonal antibodies","volume":"1","author":"Pandey S","year":"2010","unstructured":"Pandey S. Hybridoma technology for production of monoclonal antibodies. Hybridoma, 2010; 1(2):017.","journal-title":"Hybridoma"},{"key":"e_1_3_6_138_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1135"},{"issue":"2","key":"e_1_3_6_139_2","first-page":"143","article-title":"Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies","volume":"60","author":"Dudzinski DM","year":"2005","unstructured":"Dudzinski DM. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies. Food Drug Law J, 2005; 60(2):143\u2013260.","journal-title":"Food Drug Law J"},{"key":"e_1_3_6_140_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2747"},{"key":"e_1_3_6_141_2","unstructured":"Food US. Drug Administration (USFDA). Development and Licensure of Vaccines to Prevent COVID. 2018; 19."},{"key":"e_1_3_6_142_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12091992"},{"key":"e_1_3_6_143_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817411.ch19"},{"key":"e_1_3_6_144_2","unstructured":"Goulet DR. Biophysical Approaches for the Development of Stable Long-Lived Multi-Functional and Potent Antibody Therapeutics (Doctoral dissertation)."},{"key":"e_1_3_6_145_2","first-page":"1","article-title":"A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus","volume":"5","author":"Eisenberg R","year":"2003","unstructured":"Eisenberg R, , Albert D, , Stansberry J, et al. A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus. Arthritis Res Ther, 2003; 5:1\u201354.","journal-title":"Arthritis Res Ther"},{"key":"e_1_3_6_146_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006915"},{"key":"e_1_3_6_147_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88288-0"},{"key":"e_1_3_6_148_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2003.n.038"},{"issue":"4","key":"e_1_3_6_149_2","first-page":"1045","article-title":"The trastuzumab era: Current and upcoming targeted HER2+ breast cancer therapies","volume":"10","author":"Kreutzfeldt J","year":"2020","unstructured":"Kreutzfeldt J, , Rozeboom B, , Dey N, et al. The trastuzumab era: Current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res, 2020; 10(4):1045\u20131067.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_6_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102922"},{"key":"e_1_3_6_151_2","volume-title":"Gahart\u2019s 2021 Intravenous Medications-E-Book: Gahart\u2019s 2021 Intravenous Medications-E-Book","author":"Gahart BL","year":"2020","unstructured":"Gahart BL, , Nazareno AR, , Ortega M. Gahart\u2019s 2021 Intravenous Medications-E-Book: Gahart\u2019s 2021 Intravenous Medications-E-Book. Elsevier Health Sciences; 2020."},{"key":"e_1_3_6_152_2","first-page":"285","article-title":"ADVERSE EFFECTS","author":"Holmes GL","year":"2002","unstructured":"Holmes GL. ADVERSE EFFECTS. Antiepileptic Drugs, 2002:285.","journal-title":"Antiepileptic Drugs"},{"key":"e_1_3_6_153_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0775-7"},{"key":"e_1_3_6_154_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2105141"},{"key":"e_1_3_6_155_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-36358-1_6"},{"key":"e_1_3_6_156_2","doi-asserted-by":"publisher","DOI":"10.5603\/HCP.2023.0007"},{"key":"e_1_3_6_157_2","unstructured":"Kim SJ Yoon DH Kim JS et al. Phase II Brentuximab Vedotin Trial for Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas."},{"key":"e_1_3_6_158_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236125"},{"key":"e_1_3_6_159_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0145-z"},{"key":"e_1_3_6_160_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214527144"},{"issue":"1","key":"e_1_3_6_161_2","first-page":"3597609","article-title":"A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma","volume":"2016","author":"Colosia A","year":"2016","unstructured":"Colosia A, , Khan S, , Hackshaw MD, et al. A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma. Sarcoma, 2016; 2016(1):3597609.","journal-title":"Sarcoma"},{"key":"e_1_3_6_162_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119046936.ch18"},{"key":"e_1_3_6_163_2","doi-asserted-by":"publisher","DOI":"10.1006\/rtph.1998.1201"},{"key":"e_1_3_6_164_2","volume-title":"An open-label, phase Ib\/II clinical trial of CDK 4\/6 inhibitor, ribociclib (LEE011), in combination with trastuzumab or T-DM1 for advanced\/metastatic HER2-positive breast cancer","author":"Tolaney S","unstructured":"Tolaney S. An open-label, phase Ib\/II clinical trial of CDK 4\/6 inhibitor, ribociclib (LEE011), in combination with trastuzumab or T-DM1 for advanced\/metastatic HER2-positive breast cancer. Coordinating Center: Dana-Farber Cancer Institute."},{"key":"e_1_3_6_165_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i11.1400"},{"key":"e_1_3_6_166_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1036026"},{"key":"e_1_3_6_167_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0584-z"},{"key":"e_1_3_6_168_2","doi-asserted-by":"publisher","DOI":"10.5603\/HCP.2021.0014"},{"key":"e_1_3_6_169_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002267"},{"key":"e_1_3_6_170_2","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12935"},{"issue":"10","key":"e_1_3_6_171_2","first-page":"3731","article-title":"Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and\/or radiation therapy in a human breast cancer model","volume":"9","author":"Buchsbaum DJ","year":"2003","unstructured":"Buchsbaum DJ, , Zhou T, , Grizzle WE, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and\/or radiation therapy in a human breast cancer model. Clinical Cancer Research, 2003; 9(10):3731\u20133741.","journal-title":"Clinical Cancer Research"},{"key":"e_1_3_6_172_2","doi-asserted-by":"publisher","DOI":"10.3233\/BD-2010-0310"},{"issue":"24","key":"e_1_3_6_173_2","first-page":"6178","article-title":"Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines","volume":"59","author":"Soriano AF","year":"1999","unstructured":"Soriano AF, , Helfrich B, , Chan DC, et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res, 1999; 59(24):6178\u20136184.","journal-title":"Cancer Res"},{"key":"e_1_3_6_174_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.21635"},{"key":"e_1_3_6_175_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_1.S57"},{"key":"e_1_3_6_176_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0498-7"},{"key":"e_1_3_6_177_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34054"},{"key":"e_1_3_6_178_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1479983"},{"key":"e_1_3_6_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116522"},{"key":"e_1_3_6_180_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.06.004"},{"key":"e_1_3_6_181_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245765"},{"key":"e_1_3_6_182_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01069-0"},{"key":"e_1_3_6_183_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041069"},{"issue":"9","key":"e_1_3_6_184_2","first-page":"2531","article-title":"Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: Preclinical and clinical evidence","volume":"5","author":"Segovia-Mendoza M","year":"2015","unstructured":"Segovia-Mendoza M, , Gonz\u00e1lez-Gonz\u00e1lez ME, , Barrera D, et al. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: Preclinical and clinical evidence. Am J Cancer Res, 2015; 5(9):2531\u20132561.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_6_185_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.432"},{"key":"e_1_3_6_186_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.516"},{"issue":"9","key":"e_1_3_6_187_2","first-page":"695","article-title":"Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: Association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways","volume":"1","author":"Wu K","year":"2002","unstructured":"Wu K, , Wang C, , D\u2019Amico M, et al. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: Association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther, 2002; 1(9):695\u2013706.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_6_188_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0593"},{"key":"e_1_3_6_189_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"e_1_3_6_190_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.49040"},{"key":"e_1_3_6_191_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00723-5"},{"key":"e_1_3_6_192_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2002.18802.x"},{"key":"e_1_3_6_193_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8"},{"key":"e_1_3_6_194_2","doi-asserted-by":"publisher","DOI":"10.1159\/000512218"},{"key":"e_1_3_6_195_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.11"},{"key":"e_1_3_6_196_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0244"},{"key":"e_1_3_6_197_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S256708"},{"key":"e_1_3_6_198_2","unstructured":"Zahavi DJ. Antibody Depdendent Cell-Mediated Cytotoxicity (ADCC) Selection Pressure Induces Diverse and Reversible Mechanisms of Resistance (Doctoral dissertation Georgetown University)."},{"key":"e_1_3_6_199_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061475"},{"key":"e_1_3_6_200_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.22225"},{"issue":"4","key":"e_1_3_6_201_2","first-page":"733","article-title":"A critical role for HER3 in HER2-amplified and non-amplified breast cancers: Function of a kinase-dead RTK","volume":"7","author":"Dey N","year":"2015","unstructured":"Dey N, , Williams C, , Leyland-Jones B, et al. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: Function of a kinase-dead RTK. American Journal of Translational Research, 2015; 7(4):733.","journal-title":"American Journal of Translational Research"},{"key":"e_1_3_6_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.025"},{"key":"e_1_3_6_203_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10121993"},{"key":"e_1_3_6_204_2","volume-title":"Identifying Molecular Mechanisms of Resistance to Antibody Dependent Cell Mediated Cytotoxicity (ADCC).","author":"Aldeghaither DS","year":"2018","unstructured":"Aldeghaither DS. Identifying Molecular Mechanisms of Resistance to Antibody Dependent Cell Mediated Cytotoxicity (ADCC). Georgetown University; 2018."},{"key":"e_1_3_6_205_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201022666210820093608"},{"key":"e_1_3_6_206_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01544"},{"key":"e_1_3_6_207_2","first-page":"617","volume-title":"Antibody engineering & therapeutics, the annual meeting of the antibody society","author":"Pauthner M","year":"2016","unstructured":"Pauthner M, , Yeung J, , Ullman C, et al. Antibody engineering & therapeutics, the annual meeting of the antibody society December 7\u201310, 2015, San Diego, CA, USA. In MAbs 2016 Apr 2 (Vol. 8, No. 3, pp. 617\u2013652). Taylor & Francis."},{"key":"e_1_3_6_208_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00579-0"},{"key":"e_1_3_6_209_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.05.003"},{"key":"e_1_3_6_210_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"issue":"1","key":"e_1_3_6_211_2","first-page":"6663708","article-title":"Technological advancements in monoclonal antibodies","volume":"2021","author":"Santos-Neto JF","year":"2021","unstructured":"Santos-Neto JF, , Oliveira FO, , Hodel KV, et al. Technological advancements in monoclonal antibodies. ScientificWorldJournal, 2021; 2021(1):6663708.","journal-title":"ScientificWorldJournal"},{"key":"e_1_3_6_212_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0268-3"},{"key":"e_1_3_6_213_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.2c00177"},{"key":"e_1_3_6_214_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01459-y"},{"key":"e_1_3_6_215_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-541-5_5"},{"key":"e_1_3_6_216_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4175"},{"key":"e_1_3_6_217_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098206"},{"key":"e_1_3_6_218_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-017-0091-4"},{"key":"e_1_3_6_219_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.903065"},{"key":"e_1_3_6_220_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0798-2"},{"key":"e_1_3_6_221_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184543"},{"key":"e_1_3_6_222_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04467-7"},{"key":"e_1_3_6_223_2","unstructured":"Hennessy M. The perioperative setting as a platform for breast cancer."},{"key":"e_1_3_6_224_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100772"},{"key":"e_1_3_6_225_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01587-z"},{"key":"e_1_3_6_226_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0482"},{"issue":"1","key":"e_1_3_6_227_2","first-page":"352182","article-title":"Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer","volume":"2011","author":"Fiszman GL","year":"2011","unstructured":"Fiszman GL, , Jasnis MA. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int J Breast Cancer, 2011; 2011(1):352182.","journal-title":"Int J Breast Cancer"},{"key":"e_1_3_6_228_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.973955"},{"key":"e_1_3_6_229_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01873-y"},{"key":"e_1_3_6_230_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092526"},{"key":"e_1_3_6_231_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70329-7"},{"key":"e_1_3_6_232_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0163"},{"key":"e_1_3_6_233_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01108.x"},{"key":"e_1_3_6_234_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70096"},{"key":"e_1_3_6_235_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0242-5"},{"key":"e_1_3_6_236_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.0463"},{"key":"e_1_3_6_237_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111549"},{"key":"e_1_3_6_238_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00326"},{"key":"e_1_3_6_239_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.820968"},{"key":"e_1_3_6_240_2","first-page":"105","article-title":"Current therapies and latest developments in cancer treatment","volume":"57","author":"Baykara O","year":"2015","unstructured":"Baykara O. Current therapies and latest developments in cancer treatment. Horizons in Cancer Research, 2015; 57:105\u2013156.","journal-title":"Horizons in Cancer Research"},{"key":"e_1_3_6_241_2","doi-asserted-by":"publisher","DOI":"10.1039\/D4NR00680A"}],"container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mab.2024.0018","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2024.0018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2024.0018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:22:34Z","timestamp":1777666954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mab.2024.0018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":240,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4,1]]}},"alternative-id":["10.1089\/mab.2024.0018"],"URL":"https:\/\/doi.org\/10.1089\/mab.2024.0018","relation":{},"ISSN":["2167-9436","2167-9436"],"issn-type":[{"value":"2167-9436","type":"print"},{"value":"2167-9436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}